Kenai Therapeutics
↗San Diego, USA
Kenai Therapeutics is a clinical-stage biotechnology company pioneering next-generation approaches to cure neurological conditions using induced pluripotent stem cell (iPSC) technology. The company focuses on developing off-the-shelf, allogeneic neuron replacement therapies designed to be disease-modifying rather than just symptom-masking.
Formerly known as Ryne Bio, the company is advancing a robust pipeline of dopamine neuron replacement cell therapeutics. Its lead candidate, RNDP-001, is currently in Phase 1 clinical trials for the treatment of idiopathic Parkinson's disease, aiming to replace lost dopaminergic neurons and restore motor function.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:CNS therapeutics / Cell therapy
SIZE & FINANCIALS
Employees:11-50
Revenue:Pre-revenue
Founded:2022
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$89M
Investors:Alaska Permanent Fund Corporation, Cure Ventures, The Column Group, Euclidean Capital, Saisei Ventures, California Institute for Regenerative Medicine (CIRM)
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1
Modalities:Cell therapy, iPSC-derived, Allogeneic
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:FUJIFILM Cellular Dynamics (Exclusive manufacturing partnership), Lilly Gateway Labs (Research facility collaboration)
COMPETITION
Position:Emerging
Competitors:BlueRock Therapeutics, Aspen Neuroscience, Cellino, Century Therapeutics
LEADERSHIP
Key Executives:
Nicholas Manusos - CEO
Howard Federoff - CMO & Scientific Co-Founder
Derek Hei - CTO
Rajesh Mistry - CFO
Scientific Founders:Howard Federoff, Jonathan Yeh, Carter Cliff
Board Members:Jeffrey Jonas (Chair), David Fallace, Nick Manusos, Jeff Goater
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Kenai Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.